Development of masked therapeutic antibodies to limit off-target effects
US11311622B2 · kind B2 · utility
0Cited by
3References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 2, 2019 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Jul 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.